



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

26 January 2018

ANNOUNCEMENT




Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PROFIT WARNING

SUMMARY

This announcement is made by the Company in compliance with the disclosure requirements under Rule 13.09 of the HK Listing Rules and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Directors of the Company wish to inform the shareholders of the Company and potential investors that based on the preliminary assessment of the information currently available to the Board, they expect that the Group will record a loss attributable to the equity holders of the Company for the year ended 31 December 2017 of between US\$27 million (or approximately HK\$210.60 million) to US\$29 million (or approximately HK\$226.20 million), as compared to a loss attributable to the equity holders of the Company of US\$2.46 million (or approximately HK\$19.19 million) for the corresponding year in 2016.



The loss for the year ended 31 December 2017 is mainly attributable to: (i) an amortisation charge of approximately US\$28.05 million (or approximately HK\$218.79 million) on the intangible asset, being Fortacin™, a non-cash item; and (ii) the Group's operating expenses; while being offset somewhat by: (iii) a marked-to-market profit in respect of the Company's equity portfolio of financial assets at fair value through profit or loss.

The financial year concluded on 31 December 2017 and, consequently, the Company is still in the process of finalising the Group's annual results. The information contained in this announcement is only an initial assessment by the Directors based on a preliminary review of the currently available and unaudited management accounts and is not based on any financial data or information that has been audited or reviewed by the Group's auditor. The Company will publish its audited final results for the year ended 31 December 2017 as soon as practicable, but not later than 31 March 2018.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Regent Pacific Group Limited (the "**Company**" and collectively with its subsidiaries, the "**Group**") in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**HK Listing Rules**") and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The directors (the "**Directors**" or the "**Board**") of the Company wish to inform the shareholders of the Company and potential investors that based on the preliminary assessment of the information currently available to the Board, they expect that the Group will record a loss attributable to the equity holders of the Company for the year ended 31 December 2017 of between US\$27 million (or approximately HK\$210.60 million) to US\$29 million (or approximately HK\$226.20 million), as compared to a loss attributable to the equity holders of the Company of US\$2.46 million (or approximately HK\$19.19 million) for the corresponding year in 2016.

The loss for the year ended 31 December 2017 is mainly attributable to: (i) an amortisation charge of approximately US\$28.05 million (or approximately HK\$218.79 million) on the intangible asset, being Fortacin™, a non-cash item; and (ii) the Group's operating expenses;

while being offset somewhat by: (iii) a marked-to-market profit in respect of the Company's equity portfolio of financial assets at fair value through profit or loss.

The Company continues to be debt free with approximately US\$11.03 million (or approximately HK\$86.03 million) in cash and listed securities as at 31 December 2017 and remains committed, together with Recordati S.p.A. ("**Recordati**"), its commercial partner, to bringing Fortacin™ to market in France, Germany, Italy, Spain and Portugal in March 2018, followed by the launch in Greece, Romania, Czech Republic, Slovak Republic and Poland in the second half of 2018 and in the rest of Europe, Russia, the Commonwealth of Independent States (CIS) and select countries of North Africa in the coming years. In this respect, Recordati has placed its initial purchase order, and manufacturing is well advanced to achieve the commercial launch in Continental Europe on time. The Group is continuing to make progress with the Hong Kong Department of Health Drug Office and the Macau Government Health Bureau to acquire import licences to allow for the sale of Fortacin™ in Hong Kong and Macau and remains in active discussions with possible commercial partners for the sale and distribution of Fortacin™ in the remaining key markets of China, North America, Latin America and the Asia Pacific regions. The Group will continue to work closely and diligently with its commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

The financial year concluded on 31 December 2017 and, consequently, the Company is still in the process of finalising the Group's annual results. The information contained in this announcement is only an initial assessment by the Directors based on a preliminary review of the currently available and unaudited management accounts and is not based on any financial data or information that has been audited or reviewed by the Group's auditor. The Company will publish its audited final results for the year ended 31 December 2017 as soon as practicable, but not later than 31 March 2018.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, amounts denominated in US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:

James Mellon (*Chairman*)^{*}

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe^{*}

^{*} *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 26 January 2018